公开(公告)号：EP4442323A2

公开(公告)日：2024-10-09

申请号：EP24182364.0

申请日：2017-08-31

申请人： Regeneron Pharmaceuticals, Inc. ,  Sanofi Biotechnology

发明人： HAMILTON, Jennifer D. ,  SWANSON, Brian N.

IPC分类号： A61P37/08

CPC分类号： A61K39/00 ,  C07K16/2866 ,  A61K2039/50520130101 ,  A61K2039/54520130101 ,  C07K2317/7620130101 ,  A61P17/00 ,  A61P37/08 ,  A61K38/1774

摘要： The present invention provides methods for preventing or treating allergy. Also provided are methods for reducing the susceptibility to an allergen in a subject in need thereof. In certain embodiments, the subject has a disease or disorder selected from the group consisting of atopic dermatitis, asthma, allergic rhinitis, and eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody.

公开(公告)号：EP4438048A1

公开(公告)日：2024-10-02

申请号：EP22898585.9

申请日：2022-11-22

申请人： Regcell Co., Ltd. ,  OSAKA UNIVERSITY

发明人： MIKAMI, Norihisa ,  SAKAGUCHI, Shimon

IPC分类号： A61K35/17 ,  A61P1/04 ,  A61P3/10 ,  A61P5/14 ,  A61P7/06 ,  A61P9/00 ,  A61P9/14 ,  A61P13/12 ,  A61P15/00 ,  A61P17/06 ,  A61P19/02 ,  A61P21/00 ,  A61P21/04 ,  A61P25/00 ,  A61P25/02 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00 ,  A61P37/02

CPC分类号： A61K35/17 ,  A61P1/04 ,  A61P3/10 ,  A61P5/14 ,  A61P5/16 ,  A61P7/06 ,  A61P9/14 ,  A61P13/12 ,  A61P9/00 ,  A61P17/06 ,  A61P19/02 ,  A61P15/00 ,  A61P25/00 ,  A61P25/02 ,  A61P21/00 ,  A61P21/04 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  C07K14/55 ,  C12N1/00 ,  C12N5/06 ,  C12Q1/02

摘要： According to the present disclosure, there is provided a pharmaceutical composition for treating or preventing a T cell-related disorder, the pharmaceutical composition comprising an inducible regulatory T cell having high functionality and stable immunosuppressive function. T cell : The present disclosure provides a pharmaceutical composition for treating or preventing a T cell-related disorder, the pharmaceutical composition comprising, as an active ingredient, an inducible regulatory T cell having at least one feature selected from the group consisting of CTLA4 positivity, NT5E positivity, ITGAE (CD103) positivity, and AREG positivity.

公开(公告)号：EP3548510B1

公开(公告)日：2024-10-02

申请号：EP17818367.9

申请日：2017-11-30

IPC分类号： C07K14/705

CPC分类号： A61K38/00 ,  A61K8/64 ,  A61Q19/007 ,  C07K14/705 ,  A61P17/00 ,  A61P17/04 ,  A61P17/06 ,  A61P29/00 ,  A61P37/02 ,  A61P37/08

公开(公告)号：EP4427736A2

公开(公告)日：2024-09-11

申请号：EP24159031.4

申请日：2018-03-16

申请人： Bayer HealthCare LLC

发明人： Sirihorachai, Rachan ,  Bradley, Reginald ,  Rosar, Paul ,  Ekpe, Anthony ,  Joshi Charu

IPC分类号： A61K9/00

CPC分类号： A61K9/0058 ,  A61K31/438 ,  A61K47/10 ,  A61K47/12 ,  A61K47/42 ,  A61K47/36 ,  A61P37/08 ,  A61K9/0056

摘要： The present disclosure relates to chewable gel products containing a gel carrier and an active pharmaceutical ingredient (API), where the chewable gel product has an acceptable taste.

公开(公告)号：EP2262775B1

公开(公告)日：2024-09-04

申请号：EP09720914.2

申请日：2009-03-11

IPC分类号： C07D231/12 ,  A61K31/4155 ,  A61P35/00 ,  A61P37/00

CPC分类号： C07D403/12 ,  A61P1/04 ,  A61P11/00 ,  A61P11/02 ,  A61P11/06 ,  A61P13/08 ,  A61P15/00 ,  A61P17/00 ,  A61P17/04 ,  A61P17/06 ,  A61P19/00 ,  A61P19/02 ,  A61P19/06 ,  A61P19/08 ,  A61P25/00 ,  A61P25/16 ,  A61P25/28 ,  A61P29/00 ,  A61P31/18 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  A61P9/00 ,  A61P9/10

公开(公告)号：EP4421162A1

公开(公告)日：2024-08-28

申请号：EP22880937.2

申请日：2022-10-07

申请人： TAGCyx Biotechnologies Inc.

发明人： HARADA, Kaori ,  HORI, Miyuki

IPC分类号： C12N

CPC分类号： A61K31/711 ,  A61K47/55 ,  A61P1/00 ,  A61P1/16 ,  A61P3/10 ,  A61P13/10 ,  A61P9/00 ,  A61P17/00 ,  A61P17/06 ,  A61P17/14 ,  A61P19/00 ,  A61P19/02 ,  A61P15/00 ,  A61P25/28 ,  A61P27/04 ,  A61P29/00 ,  A61P27/02 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  C07K14/57 ,  C12N15/115

摘要： A purpose of the present invention is to provide an autoimmune disease therapeutic agent that can selectively inhibit IFN-γ, has no risk of biological contamination, and can be stored at room temperature. Provided is an autoimmune disease therapeutic agent containing as an active ingredient a DNA oligonucleotide having a nucleotide sequence set forth in any of SEQ ID NO:1 to 3 and selectively binding to IFN-γ. In another aspect, provided is a DNA oligonucleotide having a nucleotide sequence set forth in any of SEQ ID NO:1 to 3 and having a therapeutic effect on autoimmune diseases by selectively binding to IFN-γ.

公开(公告)号：EP3978598B1

公开(公告)日：2024-08-28

申请号：EP21198256.6

申请日：2012-11-29

IPC分类号： C12N1/20 ,  A61K35/74 ,  A61P29/00 ,  A61P37/02 ,  C12N15/09

CPC分类号： A61K35/74 ,  A61P29/00 ,  A61P31/00 ,  A61P33/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  C12R2001/14520210501 ,  C12N1/205 ,  Y02A50/30

公开(公告)号：EP4410976A2

公开(公告)日：2024-08-07

申请号：EP24167285.6

申请日：2014-03-14

申请人： Elixirgen Therapeutics, Inc.

发明人： KO, Minoru S.H.

IPC分类号： C12N15/09

CPC分类号： C12N2760/1884120130101 ,  A61K48/005 ,  A61K31/7088 ,  A61K38/1709 ,  C07K14/47 ,  C12N15/113 ,  C12N2310/1420130101 ,  C12N2310/53120130101 ,  A61P1/00 ,  A61P1/02 ,  A61P1/04 ,  A61P1/16 ,  A61P1/18 ,  A61P11/00 ,  A61P13/00 ,  A61P13/02 ,  A61P13/08 ,  A61P13/10 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P17/02 ,  A61P17/06 ,  A61P17/14 ,  A61P19/00 ,  A61P19/02 ,  A61P21/00 ,  A61P21/02 ,  A61P21/04 ,  A61P25/00 ,  A61P25/14 ,  A61P25/16 ,  A61P25/28 ,  A61P25/32 ,  A61P27/02 ,  A61P27/16 ,  A61P29/00 ,  A61P35/00 ,  A61P35/02 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  A61P5/00 ,  A61P5/38 ,  A61P7/00 ,  A61P7/02 ,  A61P7/06 ,  A61P9/00 ,  A61P9/10 ,  A61P3/10

摘要： The present disclosure relates to methods for increasing telomere length in one or more human cells and/or increasing genome stability of one or more human cells, for example by contacting one or more human cells with an agent that increases expression of Zscan4 in the one or more human cells. Methods of treating a subject in need of telomere lengthening, treating a disease or condition associated with a genomic and/or chromosome abnormality, of rejuvenating one or more human cells, of rejuvenating tissues or organs, and of rejuvenating a subject in need thereof, for example by contacting one or more human cells in the subject with an agent that increases expression of Zscan4, or by administering to a subject in need thereof, an agent that increases expression of Zscan4 are also provided.

公开(公告)号：EP3506931B1

公开(公告)日：2024-07-31

申请号：EP17771619.8

申请日：2017-08-31

IPC分类号： A61K39/00 ,  C07K16/28 ,  A61P37/08

CPC分类号： A61K39/00 ,  C07K16/2866 ,  A61K2039/50520130101 ,  A61K2039/54520130101 ,  C07K2317/7620130101 ,  A61P17/00 ,  A61P37/08 ,  A61K38/1774

公开(公告)号：EP4353324A3

公开(公告)日：2024-07-03

申请号：EP23214923.7

申请日：2015-01-12

申请人： Aurigene Oncology Limited

发明人： GUMMADI, Venkateshwar, Rao ,  SAMAJDAR, Susanta

IPC分类号： A61P37/02

CPC分类号： C07D498/04 ,  C07D519/00 ,  C07D513/04 ,  A61P1/02 ,  A61P1/04 ,  A61P1/16 ,  A61P1/18 ,  A61P11/00 ,  A61P11/02 ,  A61P11/04 ,  A61P11/06 ,  A61P13/10 ,  A61P13/12 ,  A61P15/00 ,  A61P15/14 ,  A61P17/00 ,  A61P17/04 ,  A61P17/06 ,  A61P17/14 ,  A61P19/00 ,  A61P19/02 ,  A61P21/00 ,  A61P21/04 ,  A61P25/00 ,  A61P25/04 ,  A61P25/06 ,  A61P27/02 ,  A61P27/06 ,  A61P27/12 ,  A61P27/14 ,  A61P27/16 ,  A61P29/00 ,  A61P3/00 ,  A61P3/04 ,  A61P31/00 ,  A61P35/00 ,  A61P35/02 ,  A61P3/06 ,  A61P37/02 ,  A61P37/08 ,  A61P5/00 ,  A61P7/00 ,  A61P7/02 ,  A61P7/06 ,  A61P9/00 ,  A61P9/10 ,  A61P9/12

摘要： The present invention provides bicyclic heterocyclyl kinase enzyme inhibitor compounds, and a pharmaceutically acceptable salt thereof, which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder mediated by kinase enzyme, particularly IRAK4 enzyme.